Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 3/20 | 0.44 |
| ▸ | PIK3CA | P42336 | 9/20 | 0.40 |
| ▸ | PIK3CD | O00329 | 7/20 | 0.40 |
| ▸ | ACACB | O00763 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | CSF1R | P07333 | 1/20 | 0.35 |
| ▸ | FLT3 | P36888 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20069356 | 0.85 | PIK3CD (0.42) | RETPIK3CAPIK3CDACACB | |
| SCHEMBL20152047 | 0.81 | HRH3 (0.45) | RETPIK3CAPIK3CDACACB | |
| SCHEMBL20147439 | 0.79 | RET (0.39) | RETPIK3CDESR1CSF1RFLT3 | |
| SCHEMBL29686426 | 0.79 | PIK3CD (0.54) | PIK3CAPIK3CD | |
| SCHEMBL20137611 | 0.79 | PIK3CA (0.51) | RETPIK3CAPIK3CDACACB | |
| SCHEMBL20137612 | 0.79 | PIK3CA (0.51) | RETPIK3CAPIK3CDACACB | |
| SCHEMBL25502772 | 0.79 | PIK3CA (0.41) | RETPIK3CAPIK3CDACACBESR1 | |
| SCHEMBL20147444 | 0.78 | RET (0.40) | RETPIK3CAPIK3CD | |
| SCHEMBL20147969 | 0.78 | RET (0.41) | RETPIK3CAPIK3CDESR1 | |
| SCHEMBL20069364 | 0.78 | HRH3 (0.44) | RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10881652-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2021-01-05 | — | — | US | disclosed |
| US-10441581-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2019-10-15 | — | — | US | disclosed |
| US-20180133207-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
| US-20180133207-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10881652-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | RET 1/4885PIK3CA 915/4885PIK3CD 1807/4885 |
| US-10441581-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | RET 1/4885PIK3CA 915/4885PIK3CD 1807/4885 |
| US-20180133207-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | RET 1/4885PIK3CA 915/4885PIK3CD 1807/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.